Semaglutide Pregnancy

⚠️ Important Medical Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented here should not be used to make decisions about pregnancy, medication use, or fertility without consulting a qualified healthcare professional.

Pregnancy and medication decisions are deeply personal and medically complex. Every individual situation is unique. Always consult your obstetrician, reproductive endocrinologist, or prescribing physician before making any changes to your medication regimen, especially when planning or managing a pregnancy.

FormBlends does not recommend for or against any pregnancy decisions. The clinical data referenced in this guide reflects the state of published medical literature as of March 2026 and may be updated as new research becomes available.

Table of Contents

1. Understanding Semaglutide: The Basics for Women of Reproductive Age
2. FDA Pregnancy Warnings and Regulatory Classification
3. What the Animal Studies Actually Show
4. Human Exposure Data: What We Know from Real-World Pregnancies
5. The Washout Period: Why 2 Months and How It Works
6. The “Ozempic Babies” Phenomenon: Weight Loss and Restored Fertility
7. PCOS, Insulin Resistance, and the GLP-1 Fertility Connection
8. Contraception While on GLP-1 Medications
9. Planning Your Pregnancy Timeline: A Step-by-Step Framework
10. Accidental Pregnancy on Semaglutide: What to Do
11. Preconception Health Optimization After GLP-1 Therapy
12. Managing Weight During the Transition Off Semaglutide
13. Fertility Clinic Perspectives: Semaglutide in the IVF Context
14. Breastfeeding and Semaglutide: What the Evidence Says
15. Returning to GLP-1 Therapy After Pregnancy
16. Other GLP-1 Medications and Pregnancy: Tirzepatide, Liraglutide, and More
17. Semaglutide and Male Fertility
18. Emotional Considerations: Navigating Weight, Fertility, and Identity
19. Monitoring Schedule: Before, During, and After the Transition
20. The Future of Research: Ongoing Studies and What to Watch For
21. Frequently Asked Questions (23 Questions)
22. Glossary of Key Terms
23. References and Further Reading

1. Understanding Semaglutide: The Basics for Women of Reproductive Age

Before examining the specific relationship between semaglutide and pregnancy, understand what this medication is, how it works in the body, and why its pharmacological properties matter so much in the context of reproductive health.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist - a synthetic molecule designed to mimic the action of a natural hormone your body produces every time you eat. The natural GLP-1 hormone is released from L-cells in the small intestine and plays crucial roles in blood sugar regulation, appetite control, and gastric emptying. However, natural GLP-1 is degraded within 2 to 3 minutes by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide has been engineered to resist this breakdown, giving it an elimination half-life of approximately 7 days - a factor that becomes critically important when we discuss washout periods for pregnancy planning.

Semaglutide is marketed under several brand names, each approved for different indications:

For women of reproductive age, several aspects of semaglutide pharmacology deserve special attention. First, the long half-life means the drug persists in the body for weeks after the last dose, which directly informs the washout period needed before conception. Second, semaglutide significantly slows gastric emptying - a property that provides appetite suppression but also has implications for the absorption of oral medications, including oral contraceptives. Third, the potent weight-loss effects of semaglutide can restore ovulatory function in women whose cycles had become irregular or absent due to obesity or polycystic ovary syndrome (PCOS), creating a fertility window that some women may not anticipate.

Understanding these pharmacological realities is the foundation for every other topic in this guide. The medication is powerful, its effects are wide-ranging, and the decisions surrounding its use in the context of family planning require careful thought and expert guidance. For a broader understanding of GLP-1 medications and how they work, see our comprehensive guide to GLP-1 receptor agonists.

2. FDA Pregnancy Warnings and Regulatory Classification

The regulatory status of semaglutide in pregnancy is unambiguous in its caution, even as the underlying evidence base has important nuances that patients deserve to understand.

2.1 Current FDA Labeling

The FDA-approved prescribing information for both Ozempic and Wegovy includes pregnancy-related warnings in several sections. Under the current Pregnancy and Lactation Labeling Rule (PLLR) framework - which replaced the older letter-category system (A, B, C, D, X) in 2015 - the labels provide narrative descriptions of available data rather than a single letter grade. However, many clinicians and reference databases still reference the older category designations, and semaglutide is frequently cited as equivalent to former Category X, meaning that the risk of use in pregnancy clearly outweighs any potential benefit.

The key pregnancy-related statements in the prescribing information include:

2.2 Understanding the Regulatory Framework

It is important for patients to understand what these regulatory statements do and do not tell us. The FDA pregnancy warnings for semaglutide are driven primarily by animal data, not by observed adverse outcomes in human pregnancies. This is standard practice in pharmaceutical regulation - when animal studies show concerning signals and human pregnancy data is limited, the regulatory default is to advise against use during pregnancy. This is a precautionary approach, which is appropriate given what is at stake.

The absence of human pregnancy data in the original approval studies is not because human data was deliberately excluded - it is because pregnant individuals are appropriately excluded from clinical trials as an ethical safeguard. This means that for virtually all newer medications, the initial pregnancy safety profile rests on animal studies, post-marketing surveillance, and data from accidental exposures.

2.3 International Regulatory Perspectives

Regulatory agencies outside the United States have issued similar warnings. The European Medicines Agency (EMA) states that semaglutide should not be used during pregnancy and that women of childbearing potential should use contraception during treatment. The EMA summary of product characteristics recommends discontinuation at least 2 months prior to a planned pregnancy. Health Canada and the Therapeutic Goods Administration (TGA) of Australia have adopted comparable positions.

The consistency across global regulatory bodies underscores that this is not a uniquely American interpretation but a consensus position based on the available preclinical data. The uniformity of the 2-month washout recommendation also reflects the pharmacokinetic properties of semaglutide rather than any specific human outcome data.

2.4 The Novo Nordisk Pregnancy Registry

Novo Nordisk, the manufacturer of Ozempic and Wegovy, maintains a pregnancy exposure registry to collect information on outcomes of pregnancies in which the mother was exposed to semaglutide. Healthcare providers and patients can report pregnancies that occur during semaglutide treatment. This registry is a critical component of the post-marketing safety surveillance system, and data from it will be instrumental in building the human evidence base over time.

Understanding the general safety profile of GLP-1 medications provides helpful context for interpreting pregnancy-specific warnings.

3. What the Animal Studies Actually Show

The animal reproduction studies form the primary basis for the pregnancy warnings associated with semaglutide. Understanding what these studies found - and their limitations - is important for patients trying to assess their own risk profile.

3.1 Rat Studies

In studies where semaglutide was administered to pregnant rats during the period of organogenesis (the critical window of fetal organ development), researchers observed several adverse outcomes:

• Structural abnormalities including skeletal and visceral malformations at doses that produced systemic exposure approximately 4 times the maximum recommended human dose (MRHD) based on area under the curve (AUC) comparisons
• Embryofetal mortality (increased resorptions and decreased live fetuses) at exposures approximately 4 times the MRHD
• Decreased fetal body weight at doses producing exposures comparable to or greater than the MRHD
• Maternal toxicity was also observed at these doses, including decreased food intake and body weight loss, complicating the interpretation of whether fetal effects were direct drug effects or secondary to maternal undernutrition

3.2 Rabbit Studies

Rabbit studies showed similar patterns of concern:

• Early pregnancy losses at doses producing exposures less than the MRHD based on AUC
• Skeletal abnormalities at exposures approximately 4 times the MRHD
• Increased incidence of fetal malformations at higher dose levels
• Significant maternal toxicity including marked reductions in food intake and body weight, again creating uncertainty about direct versus indirect fetal effects

3.3 Interpreting Animal Data in Context

The interpretation of animal reproduction studies requires careful nuance, and several points are relevant for patients:

Maternal toxicity confounds interpretation. Many of the fetal effects observed in animal studies occurred at doses that also caused significant maternal toxicity, particularly reduced food intake and body weight loss. In both rats and rabbits, severe maternal undernutrition can independently cause fetal growth restriction and malformations. It is difficult to disentangle the direct effects of semaglutide on fetal development from the indirect effects of maternal nutritional compromise.

Dose considerations matter. Some of the most severe effects occurred at exposure multiples well above what humans experience at therapeutic doses. While effects at lower exposure multiples are more concerning, the dose-response relationship provides context for risk assessment.

Species differences are real. Animal studies are essential tools in safety assessment, but they do not perfectly predict human outcomes. Differences in placental structure, drug metabolism, developmental timing, and sensitivity between species mean that animal findings may over- or under-estimate human risk. Many drugs that cause problems in animal studies do not cause the same problems in humans, and vice versa.

The precautionary principle applies. Despite these nuances, the responsible interpretation is that the animal data raises legitimate concerns that cannot be dismissed. Until adequate human data is available to clarify the actual risk, the precautionary approach of avoiding semaglutide during pregnancy is medically sound.

The animal data, taken together, paints a picture of a medication that clearly warrants caution during pregnancy. The findings are consistent across species and include serious outcomes. However, the prominent role of maternal toxicity in producing these outcomes, and the uncertainty inherent in extrapolating from animal models to humans, means that the actual risk to a human fetus - particularly from early, accidental, low-dose exposure - remains an open question that only human data can answer definitively.

4. Human Exposure Data: What We Know from Real-World Pregnancies

While the animal data drives the regulatory warnings, the question most women ask when facing an unexpected pregnancy on semaglutide is far more personal: what actually happens in human pregnancies with semaglutide exposure? The answer, as of 2026, is that the human data is limited but cautiously reassuring for early, accidental exposures - while being entirely insufficient to declare the medication safe during pregnancy.

4.1 Sources of Human Pregnancy Data

Human data on semaglutide exposure during pregnancy comes from several sources, each with inherent strengths and limitations:

• Pregnancy exposure registries: Novo Nordisk maintains a voluntary registry where healthcare providers can report pregnancy outcomes following semaglutide exposure. Enrollment is ongoing, and published data from this registry remains limited.
• Pharmacovigilance databases: Post-marketing adverse event reports submitted to the FDA (through the FAERS database) and to other global regulatory agencies capture spontaneously reported pregnancy outcomes. These reports are subject to reporting bias and often lack complete outcome data.
• Published case reports and case series: Individual clinical reports and small series have been published in the medical literature documenting pregnancy outcomes following inadvertent semaglutide exposure.
• Clinical trial incidental pregnancies: A small number of pregnancies occurred during the STEP and SUSTAIN clinical trial programs when participants became pregnant despite the use of contraception. These pregnancies required protocol-mandated discontinuation of the study drug.
• Retrospective database analyses: Some researchers have used claims databases and electronic health records to identify pregnancies in women who filled semaglutide prescriptions, though these studies face significant methodological challenges.

4.2 What the Human Data Shows

The available human evidence, while limited, has several notable characteristics:

No clear pattern of birth defects has emerged. Published case reports and pharmacovigilance data have not identified a consistent pattern of structural malformations associated with semaglutide exposure during early pregnancy. This is meaningful because drugs that cause birth defects in humans typically produce recognizable patterns (as seen with thalidomide, isotretinoin, or valproic acid).

Healthy live births have been reported. Multiple published reports document healthy infants born to mothers who had inadvertent semaglutide exposure during the first trimester. These cases, while individually reassuring, do not constitute proof of safety.

Spontaneous pregnancy losses have occurred. Some reported pregnancies following semaglutide exposure have ended in miscarriage. However, the baseline rate of first-trimester miscarriage in the general population is approximately 10 to 20 percent, and it is difficult to determine whether semaglutide exposure contributed to any individual loss.

The sample size is too small for definitive conclusions. This is the most critical caveat. To detect a meaningful increase in a specific birth defect or adverse outcome, large cohort studies with appropriate control groups are needed. The current human data set is not large enough to rule out moderate increases in risk. For example, to detect a doubling of a birth defect that occurs in 1 in 1,000 pregnancies, a study would need to follow thousands of exposed pregnancies.

4.3 Lessons from Related Medications

There is some relevant data from older GLP-1 receptor agonists that can inform our understanding. Liraglutide (Victoza, Saxenda), which has been available since 2010, has accumulated more human pregnancy exposure data than semaglutide. Published analyses of liraglutide pregnancy exposures have similarly not identified a clear signal of increased birth defects, though the data remains limited. Exenatide (Byetta, Bydureon), available since 2005, has the longest post-marketing history and again has not produced a definitive signal, though formal studies are lacking.

These observations from the broader GLP-1 receptor agonist class provide some degree of additional context but do not eliminate the need for semaglutide-specific human data.

4.4 The Growing Data Set

Given the millions of women of reproductive age now using semaglutide worldwide, the number of pregnancies with semaglutide exposure - both planned and unplanned - is growing rapidly. This means the human evidence base will expand considerably over the coming years. Large Nordic registry studies, health insurance claims analyses, and the ongoing manufacturer pregnancy registry are all expected to contribute meaningful data.

For now, the responsible clinical message remains: the human data does not confirm harm, but it is not yet sufficient to confirm safety. Women who experience accidental early exposure can be somewhat reassured by the absence of a clear adverse signal, while understanding that continued vigilance and monitoring are appropriate.

5. The Washout Period: Why 2 Months and How It Works

The 2-month washout period recommended before attempting conception is not arbitrary - it is rooted in the pharmacokinetic properties of semaglutide and the principles of drug elimination.

5.1 Pharmacokinetic Basis

Semaglutide has an elimination half-life of approximately 7 days (168 hours). This means that after each half-life period, approximately 50 percent of the remaining drug is cleared from the body. Pharmacologists generally consider a drug to be effectively eliminated after 5 half-lives, at which point approximately 97 percent of the drug has been cleared. For semaglutide, 5 half-lives equals approximately 35 days, or about 5 weeks.

The 2-month (approximately 60-day) recommendation provides a safety margin beyond the 5-half-life clearance point - approximately 8 to 9 half-lives, at which point more than 99.5 percent of the drug has been eliminated. This additional margin accounts for individual variability in drug metabolism and provides extra assurance.

5.2 Individual Variability

It is important to recognize that the 7-day half-life is a population average. Individual clearance rates can vary based on several factors:

• Body weight and composition: Higher body mass may influence distribution and clearance kinetics
• Renal function: While semaglutide is not primarily renally cleared, overall metabolic function affects elimination
• Hepatic function: Liver metabolism plays a role in semaglutide degradation
• Dose prior to discontinuation: Higher steady-state levels at the time of last injection mean more absolute drug to eliminate
• Duration of therapy: Longer treatment courses achieve fuller steady-state levels
• Age: Older individuals may have slightly altered clearance rates

5.3 Clinical Considerations During the Washout

The washout period is not simply a passive waiting time. Several clinical events occur during this window that patients and providers should anticipate:

Appetite returns. As semaglutide levels decline, the appetite suppression effect wanes. Most patients notice increased hunger within 1 to 3 weeks after the last dose. This is an expected and normal part of the elimination process, not a failure of willpower.

Gastric emptying normalizes. The delayed gastric emptying caused by semaglutide resolves over the washout period. This is relevant for oral medication absorption, including the resumption of oral contraceptive reliability if used during the transition period.

Blood glucose changes. For women with type 2 diabetes or insulin resistance, blood glucose levels may rise as the glycemic effects of semaglutide diminish. Monitoring and alternative management strategies should be in place.

Menstrual cycle changes. Some women experience changes in menstrual cycle length or regularity as the medication clears. For those whose cycles became more regular on semaglutide due to weight loss, the question of whether regularity persists after discontinuation is important for conception timing.

The washout period should be viewed as an active preparation phase, not merely as waiting. Working with your healthcare provider during this time to optimize nutritional status, confirm ovulatory function, complete preconception testing, and establish behavioral strategies for weight maintenance sets the stage for a healthier pregnancy.

6. The “Ozempic Babies” Phenomenon: Weight Loss and Restored Fertility

Perhaps no aspect of the semaglutide-pregnancy conversation has captured public attention more than the phenomenon popularly known as “Ozempic babies” - a term that describes the wave of unexpected pregnancies among women taking GLP-1 receptor agonist medications. While the term is colloquial and somewhat reductive, the underlying biology is well-established and medically significant.

6.1 The Biology Behind Unexpected Pregnancies

The connection between weight loss and restored fertility is not new or unique to GLP-1 medications. Decades of research in reproductive endocrinology have established that excess body weight can impair ovulatory function through several interconnected mechanisms:

Hyperinsulinemia and insulin resistance are hallmarks of obesity and directly contribute to ovulatory dysfunction. Elevated insulin levels stimulate the ovaries to produce excess androgens (male hormones), which interfere with follicular development and ovulation. When weight loss reduces insulin resistance - and semaglutide is particularly effective at this - the androgenic suppression of ovulation can lift, restoring normal ovulatory cycles.

Altered adipokine signaling from excess adipose tissue disrupts the hypothalamic-pituitary-ovarian (HPO) axis. Leptin, produced by fat cells, plays a permissive role in reproduction. Both excessive and deficient leptin levels impair hypothalamic gonadotropin-releasing hormone (GnRH) pulsatility, disrupting the normal hormonal cascade needed for ovulation. Weight loss normalizes leptin signaling and restores the HPO axis.

Chronic low-grade inflammation associated with obesity creates an adverse hormonal environment. Inflammatory cytokines from visceral fat tissue interfere with ovarian function and implantation. Weight loss reduces this inflammatory burden.

Sex hormone-binding globulin (SHBG) levels are typically low in obesity, leading to higher free androgen levels. Weight loss increases SHBG, binding more androgens and reducing their suppressive effect on ovulation.

6.2 Why GLP-1 Medications Create a Heightened Risk

While any weight loss method can restore ovulatory function, GLP-1 receptor agonists like semaglutide create a particularly notable risk for several reasons:

• Speed and magnitude of weight loss: Semaglutide produces average weight loss of 15 to 17 percent of body weight in clinical trials, with many patients losing significantly more. This rapid, substantial weight loss can restore ovulatory function within weeks to months, before patients realize their fertility status has changed.
• Insulin sensitization beyond weight loss: GLP-1 receptor agonists improve insulin sensitivity through mechanisms independent of weight loss, including direct pancreatic beta-cell effects and reduced hepatic glucose output. This dual action may restore ovulatory function even before maximum weight loss is achieved.
• Potential impact on oral contraceptive absorption: Semaglutide slows gastric emptying, which may theoretically alter the absorption kinetics of oral contraceptive pills, potentially reducing their effectiveness. While this has not been definitively proven to cause contraceptive failures, it adds an additional layer of vulnerability.
• Large population of women of reproductive age: Millions of women aged 18 to 45 now use semaglutide for weight management. Even a small percentage experiencing restored fertility creates a numerically significant number of unexpected pregnancies.
• Assumption of infertility: Many women with long-standing obesity and irregular or absent periods may have assumed they were subfertile or infertile. The resumption of ovulatory cycles can come as a surprise, catching women who were not using contraception because they did not believe they could conceive.

6.3 Quantifying the Phenomenon

Precise statistics on the “Ozempic baby” phenomenon are difficult to establish, as there is no centralized tracking system for unexpected pregnancies in women on GLP-1 medications. However, several data points provide context:

• Surveys of reproductive endocrinologists have reported increased referrals from women who conceived unexpectedly while on GLP-1 therapy
• Social media platforms and patient forums have seen substantial growth in posts from women reporting surprise pregnancies on semaglutide, tirzepatide, and other GLP-1 agonists
• Pharmacovigilance databases show an increasing number of pregnancy reports in the semaglutide post-marketing surveillance data
• The STEP clinical trial programs reported pregnancies despite the requirement for participants to use contraception, indicating that even with directed counseling, breakthrough pregnancies occur

6.4 The Clinical Significance

The “Ozempic baby” phenomenon underscores a critical clinical message: every woman of reproductive age starting a GLP-1 receptor agonist should receive proactive contraception counseling, regardless of her stated reproductive plans. This counseling should include an explanation that weight loss can restore fertility, a discussion of contraceptive options that are not dependent on gastric absorption, and clear instructions about the washout period should she decide she wants to become pregnant.

For women who are actively hoping to become pregnant, the fertility-restoring effects of semaglutide-driven weight loss are potentially good news - when managed thoughtfully with appropriate medication discontinuation and washout before conception. The key is planning and awareness. Understanding how GLP-1 weight loss medications work helps contextualize why these fertility changes occur.

7. PCOS, Insulin Resistance, and the GLP-1 Fertility Connection

Polycystic ovary syndrome (PCOS) affects approximately 8 to 13 percent of women of reproductive age worldwide and is the most common cause of anovulatory infertility. The intersection of PCOS, insulin resistance, and GLP-1 therapy is particularly important because it is in this population that the fertility-restoring effects of semaglutide may be most pronounced - and where the implications for pregnancy planning are most significant.

7.1 The PCOS-Insulin Resistance-Anovulation Pathway

Insulin resistance is present in an estimated 50 to 70 percent of women with PCOS, and it is a central driver of the syndrome’s reproductive manifestations. The pathophysiological chain works as follows:

1. Insulin resistance leads to compensatory hyperinsulinemia (elevated insulin levels)
2. Excess insulin stimulates ovarian theca cells to overproduce androgens (primarily testosterone and androstenedione)
3. Excess insulin simultaneously suppresses hepatic production of SHBG, further increasing free androgen levels
4. Elevated androgens disrupt the normal follicular maturation process in the ovary, leading to follicular arrest
5. Arrested follicles accumulate as the characteristic “cysts” visible on ultrasound
6. Without a dominant follicle reaching maturity, ovulation does not occur (anovulation)
7. Anovulation leads to irregular or absent menstrual periods and infertility

7.2 How GLP-1 Therapy Intervenes

Semaglutide and other GLP-1 receptor agonists intervene at multiple points in this pathway:

Weight loss reduces insulin resistance. The 15 to 20 percent body weight reduction typically achieved with semaglutide produces significant improvements in insulin sensitivity. As insulin levels fall, the androgenic stimulation of the ovaries decreases, and the hormonal environment becomes more permissive for ovulation. Research has shown that even 5 to 10 percent weight loss can restore ovulatory cycles in a significant proportion of women with PCOS.

Direct insulin-sensitizing effects. Beyond weight loss, GLP-1 receptor agonists improve insulin sensitivity through direct effects on pancreatic beta-cell function, hepatic glucose metabolism, and possibly peripheral insulin action. This means that improvements in the hormonal milieu may begin before maximum weight loss is achieved.

Reduced inflammation. GLP-1 receptor agonists have demonstrated anti-inflammatory properties that may contribute to improved ovarian function beyond what weight loss alone would produce. Chronic inflammation is increasingly recognized as a contributor to PCOS pathophysiology.

7.3 Research Evidence

Several studies have examined the effects of GLP-1 receptor agonists on reproductive parameters in women with PCOS:

• Studies using liraglutide in women with PCOS demonstrated improved menstrual regularity, increased ovulation rates, and reduced androgen levels compared to placebo
• Combination therapy with liraglutide plus metformin showed additive benefits on insulin sensitivity and ovulation rates compared to either agent alone
• Preliminary data on semaglutide in PCOS populations suggests similar or superior improvements in metabolic and reproductive parameters
• The STEP trials, while not specifically enrolling PCOS patients, included women with the condition, and subgroup analyses suggest strong metabolic improvements in this population

7.4 Clinical Implications for Women with PCOS

For women with PCOS who are taking semaglutide, the fertility implications cut both ways:

For those not wanting pregnancy: The restoration of ovulation represents a genuine risk of unintended pregnancy. Contraception is essential, and non-oral methods are preferred. Women who have not had a period in months or years should not assume they cannot conceive once GLP-1 therapy begins producing weight loss.

For those wanting pregnancy: The weight loss and insulin sensitization from semaglutide may be strategically valuable as a pre-conception optimization tool. Working with a reproductive endocrinologist to plan a semaglutide course followed by appropriate discontinuation and washout can potentially improve the chances of natural conception or the success of assisted reproductive technologies.

The relationship between PCOS, GLP-1 therapy, and fertility underscores why personalized medical guidance is essential. The same medication effect - restored ovulation - can be either a welcome development or an urgent concern, depending on the patient’s reproductive goals. Understanding the broader role of GLP-1 in insulin resistance provides additional context for PCOS patients.

8. Contraception While on GLP-1 Medications

Given the potential for GLP-1 medications to restore fertility in women who may not anticipate it, and the need to prevent pregnancy during treatment and for at least 2 months after discontinuation, contraception counseling is a critical component of semaglutide prescribing for women of reproductive age.

8.1 The Oral Contraceptive Absorption Question

One of the most frequently asked questions about contraception and GLP-1 medications is whether semaglutide reduces the effectiveness of oral contraceptive pills (OCPs). This concern arises from the well-documented effect of semaglutide on gastric emptying.

A pharmacokinetic interaction study conducted by Novo Nordisk evaluated the effect of semaglutide on the absorption of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel. The study found that semaglutide did not reduce the overall bioavailability (total absorption) of either contraceptive component. However, it did alter the absorption kinetics - specifically, it reduced the peak concentration (Cmax) of ethinyl estradiol by approximately 12 percent and delayed the time to peak concentration (Tmax) by approximately 1.5 hours.

The clinical significance of this pharmacokinetic change is debated. While the total amount of drug absorbed was similar, the lower peak concentration could theoretically reduce contraceptive efficacy in some individuals, particularly if combined with other factors that affect oral contraceptive reliability (missed doses, vomiting, diarrhea, drug interactions). The FDA prescribing information does not explicitly state that oral contraceptives are ineffective with semaglutide, but many clinicians recommend non-oral contraceptive methods as a precautionary measure.

8.2 Contraceptive Options for Women on GLP-1 Therapy

8.3 Clinical Recommendations

Based on the available evidence and the precautionary principle, most experts recommend the following approach to contraception for women on GLP-1 therapy:

• First-line: Long-acting reversible contraception (IUD or implant) offers the highest efficacy and is completely unaffected by changes in gastric emptying. IUDs have the added advantage of rapid return to fertility upon removal.
• Acceptable alternatives: Transdermal patches, vaginal rings, and injectable contraceptives bypass the GI tract and are not expected to interact with GLP-1 medications.
• If using oral contraceptives: Consider taking the pill at a consistent time relative to meals, discuss with your provider whether a backup method is advisable, and be especially vigilant about missed doses or GI symptoms (vomiting, diarrhea) that could further reduce absorption.
• Continue contraception through the washout: Contraception should be maintained for the full 2-month washout period after the last dose of semaglutide. Do not assume that stopping semaglutide means fertility reverts to its pre-treatment state; the metabolic improvements from weight loss may persist.

The choice of contraception is deeply personal, and what works best depends on individual medical history, preferences, lifestyle, and reproductive plans. An open conversation with your healthcare provider about both your GLP-1 therapy and your contraceptive needs is essential.

9. Planning Your Pregnancy Timeline: A Step-by-Step Framework

For women who are taking semaglutide and planning to become pregnant in the future, a structured timeline approach can help ensure the safest possible transition. This framework is intended as a discussion guide for conversations with your healthcare team - not as a replacement for individualized medical advice.

9.1 Phase 1: Active Treatment with Family Planning Awareness (6+ Months Before Target Conception)

During this phase, you continue semaglutide treatment while establishing the foundation for a healthy pregnancy:

• Use reliable contraception (preferably non-oral methods) throughout treatment
• Begin prenatal vitamins, particularly folic acid (400-800 mcg daily, or higher if your provider recommends based on your risk profile)
• Optimize nutrition quality while on semaglutide, focusing on nutrient density to build stores for pregnancy
• Establish a regular exercise routine that you can maintain or adapt during pregnancy
• Build sustainable eating habits that will serve you when the appetite-suppressing effects of semaglutide wear off
• Discuss your pregnancy timeline with your prescribing provider so they can help plan the medication transition
• If you have diabetes: Work on optimizing glycemic control and discuss alternative diabetes medications that are pregnancy-compatible (such as insulin or metformin)
• Schedule preconception counseling with your OB/GYN or a maternal-fetal medicine specialist if you have additional risk factors

9.2 Phase 2: Discontinuation and Washout (2-3 Months Before Target Conception)

This is the transition phase where you stop semaglutide and allow it to clear your system:

• Take your final dose of semaglutide as directed by your provider
• Continue contraception throughout the entire washout period
• Schedule preconception lab work: complete blood count, metabolic panel, thyroid function, hemoglobin A1c (if diabetic or insulin resistant), vitamin D, iron studies, folate level, rubella immunity, and STI screening
• If transitioning diabetes medications: Begin pregnancy-safe alternatives as your provider directs; do not leave diabetes unmanaged during the washout
• Anticipate appetite changes and have strategies in place (meal planning, portion awareness, behavioral techniques) to manage weight without medication support
• Track your menstrual cycle to establish regularity and predict ovulation timing once you begin trying to conceive
• Continue prenatal vitamins and exercise
• Address any GI changes: as gastric emptying normalizes, you may experience changes in digestion, hunger patterns, and bowel habits

9.3 Phase 3: Active Conception (After Washout Period Completion)

Once at least 2 months have passed since your last semaglutide dose:

• Discontinue contraception when you are ready to begin trying to conceive
• Use ovulation tracking methods (basal body temperature, ovulation predictor kits, cervical mucus monitoring) to optimize timing
• Maintain the healthy habits established during treatment
• Manage expectations: even with optimal timing, the average monthly probability of conception is approximately 20 to 25 percent for couples without known fertility issues, so it may take several cycles
• Seek evaluation if you have not conceived after 6 months of trying (for women over 35) or 12 months (for women under 35), or sooner if you have known fertility risk factors

9.4 Visual Planning Timeline

This timeline is a general framework. Your healthcare provider may adjust it based on your individual medical history, the duration and dose of your semaglutide treatment, any complicating health conditions, and your age and fertility status. The key principle is that planning ahead creates the safest path forward.

10. Accidental Pregnancy on Semaglutide: What to Do

Despite the best planning, accidental pregnancies occur - and in the era of widespread GLP-1 use, a growing number of women discover they are pregnant while still taking semaglutide. If this happens to you, the following information may help guide your next steps. However, we want to emphasize from the outset: contacting your healthcare provider should be your first action.

10.1 Immediate Steps

1. Stop semaglutide immediately. Do not take any additional doses. If you have an upcoming injection scheduled, skip it. There is no need for a taper; stopping abruptly is appropriate in this situation.
2. Contact your healthcare provider. Call your prescribing physician or obstetrician as soon as possible. Explain that you have been taking semaglutide and have discovered a pregnancy. They will guide you through next steps specific to your situation.
3. Do not panic. We say this not to minimize the situation, but because the available human data - while limited - has not established a clear pattern of adverse outcomes from early accidental exposure. Stress and anxiety are understandable, but the evidence at this time does not point to an emergency.
4. Document the timing. Note the date of your last semaglutide dose, the estimated date of conception or last menstrual period, and the dose you were taking. This information will help your healthcare provider assess the exposure window.
5. Begin or continue prenatal vitamins if you have not already been taking them.

10.2 Understanding the Exposure Context

Several factors influence the potential significance of semaglutide exposure during early pregnancy:

Timing of exposure relative to conception. The first 2 weeks after fertilization (before the missed period) represent the “all-or-nothing” period in embryology. During this window, a harmful exposure either causes failure of implantation (and the pregnancy does not continue) or the embryo recovers fully with no lasting damage. The period of highest vulnerability for structural birth defects is during organogenesis, approximately weeks 3 through 8 after conception (weeks 5 through 10 of gestational age).

Dose at the time of exposure. Lower doses may carry less risk than higher doses, though the relationship between dose and fetal effects from semaglutide in humans is not established.

Duration of exposure during pregnancy. Early detection and prompt discontinuation limit the total drug exposure during the vulnerable window. This is one reason why pregnancy testing is important for women on semaglutide who experience menstrual irregularity or missed periods.

10.3 What Your Provider May Recommend

Depending on your specific circumstances, your healthcare provider may recommend:

• Detailed early ultrasound to assess fetal development and viability, typically at 6 to 8 weeks of gestation
• Referral to a maternal-fetal medicine specialist for additional counseling and monitoring, particularly if exposure occurred during the organogenesis window
• Genetic counseling to discuss the available data and help you understand the risk-benefit space
• Enhanced fetal monitoring with an anatomy ultrasound at 18 to 20 weeks to assess for structural abnormalities
• Serial growth ultrasounds if there is concern about fetal growth restriction
• Reporting to the pregnancy registry - your provider may offer to enroll your pregnancy in the manufacturer’s pregnancy exposure registry, contributing to the evidence base that will help future patients

10.4 Emotional Support

Discovering a pregnancy while on a medication with pregnancy warnings can provoke intense anxiety, guilt, and fear. These emotions are valid and understandable. It may help to know that:

• You did nothing wrong. Many women become pregnant accidentally on medications, and the healthcare system has frameworks for managing these situations.
• The available human data, while limited, has not identified a clear pattern of birth defects from semaglutide exposure in early pregnancy.
• Pregnancy counseling and support services are available and can help you process your emotions and make informed decisions.
• Your healthcare team is there to support you, not to judge you. Be honest with them about your medication history so they can provide the best possible care.

11. Preconception Health Optimization After GLP-1 Therapy

The period between stopping semaglutide and becoming pregnant offers a valuable window for preconception health optimization. The nutritional and metabolic changes that occur during GLP-1 therapy - both positive and potentially concerning - deserve attention during this transition.

11.1 Nutritional Considerations

Semaglutide significantly reduces food intake, and while this produces beneficial weight loss, it can also lead to suboptimal intake of certain nutrients that are critical for pregnancy:

Folate. Adequate folate is essential for preventing neural tube defects, and supplementation should begin at least one month before conception. Women who have been eating less due to semaglutide may have lower dietary folate intake. Supplementation with 400 to 800 mcg of folic acid daily is standard; women with BMI over 30, a history of bariatric surgery, or prior neural tube defect-affected pregnancies may need 4 mg daily.

Iron. Reduced food intake on semaglutide may contribute to lower iron stores. Iron deficiency is already common in women of reproductive age due to menstrual losses, and it can worsen during pregnancy as blood volume expands. Checking ferritin levels during the washout period and supplementing as needed is advisable.

Vitamin D. Vitamin D deficiency is prevalent in the general population and may be exacerbated by reduced dietary intake during GLP-1 therapy. Adequate vitamin D is important for calcium metabolism, immune function, and fetal development.

Protein. Adequate protein intake is important for maintaining lean body mass during the transition off semaglutide and for supporting fetal growth during pregnancy. Women transitioning off GLP-1 therapy should aim for approximately 1.0 to 1.2 grams of protein per kilogram of body weight daily.

Omega-3 fatty acids. DHA and EPA are important for fetal brain and eye development. If dietary intake of fatty fish has been low during semaglutide treatment, supplementation or increased dietary intake during the preconception period is beneficial.

Vitamin B12. GLP-1 receptor agonists can reduce vitamin B12 absorption by slowing gastric emptying and potentially reducing intrinsic factor availability. B12 deficiency can cause anemia and neurological complications and is associated with adverse pregnancy outcomes. Checking B12 levels and supplementing if low is recommended.

11.2 Metabolic Monitoring

For women with type 2 diabetes or insulin resistance, the washout period requires careful metabolic monitoring:

• Blood glucose monitoring: Frequency and method should be guided by your provider, but expect that glucose levels may rise as semaglutide effects wane
• HbA1c assessment: A preconception HbA1c provides a baseline for monitoring glycemic control during the transition. The target for preconception glycemic control is generally HbA1c below 6.5 percent, though individualized targets may vary
• Transition to pregnancy-safe medications: If glucose-lowering therapy is needed, insulin and metformin are the most established options during pregnancy. Your provider will guide this transition
• Thyroid function: Screen for thyroid disorders, which are common in women of reproductive age and can affect fertility and pregnancy outcomes

11.3 Lean Body Mass Assessment

As discussed in our guide to GLP-1 weight loss medications, significant weight loss on semaglutide involves both fat loss and some lean mass loss. Adequate lean body mass is important for pregnancy, supporting metabolic health, physical stamina, and overall maternal well-being. The preconception period is an ideal time to:

• Engage in resistance training to maintain or rebuild lean mass
• Ensure protein intake is sufficient to support muscle maintenance
• Consider body composition assessment (DEXA scan or bioimpedance) if there is concern about excessive lean mass loss

12. Managing Weight During the Transition Off Semaglutide

One of the most significant concerns for women stopping semaglutide in preparation for pregnancy is weight regain. This concern is valid - research consistently shows that most individuals regain some weight after discontinuing GLP-1 medications - but understanding the nuances can help manage expectations and develop effective strategies.

12.1 Understanding Post-Discontinuation Weight Trajectories

The STEP 1 trial extension data showed that participants who discontinued semaglutide regained approximately two-thirds of the weight they had lost within one year. However, several factors make the pregnancy context somewhat different from the general population data:

• The discontinuation period is planned and intentional, not indefinite. For many women, the goal is a time-limited period off medication (pregnancy and potentially breastfeeding) before considering resumption.
• Pregnancy itself involves expected weight gain. The question shifts from “how do I avoid gaining weight?” to “how do I gain an appropriate amount of weight for a healthy pregnancy?”
• Behavioral habits established during treatment may persist to varying degrees after discontinuation, providing some buffer against rapid regain.
• Individual variability is significant. Some women maintain most of their weight loss for extended periods, while others experience more rapid regain. Factors that influence this include the duration of treatment, the amount of weight lost, physical activity level, dietary habits, and metabolic factors.

12.2 Strategies for Managing the Transition

While some weight fluctuation is normal and expected during the transition off semaglutide and into pregnancy, several evidence-based strategies can help:

Establish eating patterns before stopping. In the weeks before your final dose, consciously practice the eating behaviors and portion sizes you want to maintain after medication support is removed. Use meal planning, mindful eating techniques, and regular meal timing to build routines that do not depend on pharmaceutical appetite suppression.

Prioritize protein and fiber. These macronutrients provide the greatest satiety per calorie and can partially compensate for the loss of semaglutide’s appetite-suppressing effects. Aim for protein at every meal and snack, and include high-fiber foods (vegetables, legumes, whole grains) to promote fullness.

Maintain or increase physical activity. Exercise supports weight maintenance through caloric expenditure, muscle preservation, and metabolic benefits. Regular physical activity also improves fertility and is beneficial during pregnancy. The ACOG recommends at least 150 minutes of moderate-intensity aerobic activity per week for pregnant individuals, and this level can be established before conception.

Monitor weight without obsessing. Regular weigh-ins can provide useful feedback, but it is important to maintain a healthy perspective. Some weight fluctuation is normal, and the goal during the preconception period is to maintain a generally stable trajectory, not to prevent every pound of change.

Consider working with a registered dietitian. A dietitian experienced in both weight management and prenatal nutrition can help you develop an eating plan that supports weight maintenance during the washout and transitions smoothly into a prenatal nutrition plan.

12.3 Appropriate Gestational Weight Gain

Once pregnant, weight gain is both expected and necessary for a healthy pregnancy. The appropriate amount of gestational weight gain depends on your pre-pregnancy BMI:

For women who have lost significant weight on semaglutide, the relevant BMI category is the one that applies at the time of conception, not the pre-treatment weight. This is an important distinction - a woman who was in the obese category before semaglutide but is now in the overweight or normal category will have different gestational weight gain targets.

12.4 The Benefits of Pre-Pregnancy Weight Loss

While the focus on weight management can feel stressful, it is worth highlighting the significant benefits that weight loss achieved before pregnancy confers:

• Reduced risk of gestational diabetes mellitus (GDM): Obesity is a major risk factor for GDM, and achieving a lower BMI before pregnancy significantly reduces this risk
• Lower risk of preeclampsia and hypertensive disorders: Pre-pregnancy obesity substantially increases the risk of preeclampsia; weight loss reduces this risk
• Reduced cesarean delivery rates: Maternal obesity is associated with higher rates of cesarean section; lower BMI at conception improves the likelihood of vaginal delivery
• Lower risk of macrosomia: Babies born to mothers with lower BMI are less likely to be excessively large, reducing birth injury risk
• Reduced risk of neural tube defects: Maternal obesity is associated with an increased risk of neural tube defects independent of folate status
• Improved fertility: As discussed earlier, weight loss restores ovulatory function and improves conception rates
• Better assisted reproduction outcomes: For women pursuing IVF, lower BMI is associated with better response to stimulation, higher pregnancy rates, and lower miscarriage rates

These benefits persist even if some weight is regained after stopping semaglutide, as long as the individual remains at a lower weight than their pre-treatment baseline at the time of conception.

13. Fertility Clinic Perspectives: Semaglutide in the IVF Context

Reproductive endocrinology clinics have seen a dramatic increase in patients who are using or have recently used GLP-1 medications. The intersection of semaglutide with assisted reproductive technologies (ART) raises unique considerations that are becoming an increasingly important part of fertility practice.

13.1 Pre-IVF Weight Optimization

Many reproductive endocrinologists now view GLP-1 medications as a potential tool for pre-IVF weight optimization. Obesity negatively affects IVF outcomes through multiple mechanisms: impaired ovarian response to stimulation, reduced oocyte quality, lower fertilization rates, reduced implantation rates, and higher miscarriage rates. For patients with obesity-related subfertility, achieving significant weight loss before an IVF cycle can improve the likelihood of success.

A typical approach might involve:

1. Initiating semaglutide therapy 6 to 12 months before a planned IVF cycle to achieve meaningful weight loss
2. Monitoring metabolic improvements (insulin, glucose, lipids, inflammatory markers) during treatment
3. Discontinuing semaglutide at least 2 months before the planned egg retrieval or embryo transfer
4. Proceeding with the IVF cycle once the washout period is complete

This approach allows the patient to benefit from the metabolic improvements of GLP-1 therapy while respecting the safety requirement for drug clearance before conception.

13.2 Egg Freezing Considerations

For women who want to freeze eggs (oocyte cryopreservation) while on semaglutide, the calculus is somewhat different. Since egg freezing does not involve embryo implantation or pregnancy, the pregnancy-related concerns about semaglutide do not directly apply to the retrieval procedure itself. However, there are theoretical considerations about whether semaglutide could affect oocyte quality through its effects on ovarian blood flow, hormonal milieu, or nutritional status. Most fertility specialists recommend discontinuing semaglutide before ovarian stimulation, though the evidence base for this recommendation is limited.

13.3 Anesthesia and Procedural Considerations

GLP-1 medications have become a significant concern for anesthesiologists due to their effects on gastric emptying. Delayed gastric emptying increases the risk of aspiration during sedation or general anesthesia - a potentially life-threatening complication. The American Society of Anesthesiologists (ASA) has issued guidance recommending that GLP-1 agonists be held before elective procedures requiring sedation or anesthesia.

For fertility procedures requiring sedation (such as egg retrieval under IV sedation or general anesthesia), this means:

• Semaglutide should be held before procedures requiring sedation, with the specific timing guided by your anesthesiologist and reproductive endocrinologist
• Fasting protocols may be extended beyond standard guidelines
• Your care team should be informed about your GLP-1 medication use, including the date of your last dose

13.4 Emerging Research in Reproductive Endocrinology

The rapid growth in GLP-1 use among women of reproductive age has stimulated significant research interest in the reproductive endocrinology community. Active areas of investigation include:

• The effect of semaglutide on oocyte quality and ovarian reserve markers
• Optimal timing of semaglutide discontinuation relative to IVF cycle start
• Whether the metabolic benefits of semaglutide translate to improved IVF outcomes compared to lifestyle-only weight loss
• The safety and efficacy of short-course GLP-1 therapy specifically as a pre-IVF intervention
• Long-term reproductive outcomes in women who conceived after GLP-1-mediated weight loss

As this research matures, fertility clinics will be able to provide increasingly evidence-based guidance on the role of GLP-1 medications in the reproductive medicine toolkit. For a thorough overview of how compounded formulations fit into this space, see our guide to GLP-1 compounding pharmacies.

14. Breastfeeding and Semaglutide: What the Evidence Says

For women who have postponed semaglutide treatment during pregnancy, the question of whether and when the medication can be resumed while breastfeeding is important. The current evidence is limited but points toward caution.

14.1 What the Animal Data Shows

Animal studies with semaglutide in lactating rats demonstrated that semaglutide (or its metabolites) is present in breast milk. This finding is not surprising given the molecular properties of semaglutide - as a modified peptide with a long half-life and significant protein binding, some transfer into milk is pharmacologically expected.

In the animal studies, pups nursed by semaglutide-treated dams showed reduced body weight and delayed growth. However, these findings must be interpreted with the same caveats that apply to the pregnancy animal data: the doses used, species differences, and the confounding effect of reduced milk production (which itself can result from the appetite-suppressing effects of the drug on the mother) all affect interpretation.

14.2 Human Lactation Data

As of March 2026, there are no published human studies specifically measuring semaglutide concentrations in breast milk or evaluating the effects of maternal semaglutide use on breastfed infants. This absence of data is the primary driver of the recommendation against use during breastfeeding - it is not possible to confirm safety without data to evaluate.

Several theoretical considerations are relevant:

• Oral bioavailability of peptides: Semaglutide is a peptide molecule, and peptides are generally poorly absorbed from the infant gastrointestinal tract. This suggests that even if semaglutide is present in breast milk, systemic absorption by the nursing infant may be minimal. However, the neonatal gut may be more permeable to large molecules than the adult gut, and semaglutide’s engineered resistance to enzymatic degradation means it may persist longer in the infant’s GI tract.
• Effect on milk production: Semaglutide’s appetite suppression could theoretically reduce caloric intake below the level needed to sustain adequate milk production. Lactation requires approximately 500 additional calories per day, and the reduced food intake associated with GLP-1 therapy could compromise milk supply.
• Infant weight gain: Any medication that could potentially affect an infant’s appetite or growth trajectory is a concern during the critical growth period of the first year of life.

14.3 Clinical Guidance

Given the lack of human lactation data, the following guidance reflects current clinical consensus:

• Most providers recommend against semaglutide use while breastfeeding, based on the precautionary principle
• The decision involves weighing the benefits of breastfeeding, the benefits of maternal weight management, and the unknown risks of infant exposure
• If a woman chooses not to breastfeed (or when breastfeeding is completed), semaglutide can be resumed with her provider’s guidance
• If a woman is considering early discontinuation of breastfeeding specifically to resume semaglutide, a thoughtful discussion with her healthcare team about the relative benefits and risks is appropriate - this is a personal decision with valid considerations on both sides
• Partial breastfeeding (supplementing with formula) does not change the recommendation regarding semaglutide, as the infant would still be exposed through breast milk

14.4 Alternative Approaches During Breastfeeding

For women who are motivated to manage their weight during breastfeeding but cannot use semaglutide, several evidence-based approaches are available:

• Moderate caloric restriction: A modest caloric deficit (300-500 calories below maintenance, not below total lactation needs) can support gradual weight loss without compromising milk production
• Physical activity: Exercise during breastfeeding is safe and does not adversely affect milk composition or infant growth. Moderate-intensity exercise 3 to 5 times per week supports postpartum weight management
• Breastfeeding itself: Lactation increases energy expenditure by approximately 500 calories per day, and many women experience gradual weight loss during breastfeeding even without deliberate restriction
• Behavioral counseling: Working with a dietitian or weight management counselor can provide structure and accountability during the postpartum period

15. Returning to GLP-1 Therapy After Pregnancy

For many women, the plan was always to resume semaglutide after pregnancy and breastfeeding. Understanding the timing, practicalities, and expectations for this return helps set the stage for a smooth transition.

15.1 Timing of Resumption

The appropriate time to restart semaglutide depends primarily on breastfeeding status:

• Not breastfeeding: Your provider may consider restarting semaglutide after the standard 6-week postpartum recovery period, once you have been medically cleared and any postpartum complications have been addressed. Some providers prefer to wait slightly longer, particularly after cesarean delivery.
• Breastfeeding and planning to wean: Semaglutide can be started once breastfeeding is fully completed. There is no specific washout period needed between the last breastfeeding session and semaglutide initiation, since the concern is about drug transfer to the infant, not about a residual effect of breastfeeding on the medication.
• Planning another pregnancy: If you are considering another pregnancy in the near future, the decision to restart semaglutide should factor in the time needed for treatment, the 2-month washout before the next conception, and the practical realities of managing a new infant while on a medication that suppresses appetite.

15.2 Starting Over vs. Resuming

After a prolonged period off semaglutide (the duration of pregnancy plus any breastfeeding period), most providers recommend restarting with the standard dose-escalation protocol rather than jumping back to the previous maintenance dose. This is because:

• GI tolerance to semaglutide diminishes after discontinuation, and restarting at a high dose is likely to produce significant nausea and vomiting
• The standard escalation schedule (starting at 0.25 mg weekly for Ozempic/Wegovy) allows the body to readjust gradually
• Some individuals may reach adequate efficacy at a lower dose than they previously required, so titrating up allows for finding the optimal dose

15.3 Postpartum Weight Management Context

The postpartum period involves unique physical and emotional dimensions that affect weight management. Women resuming semaglutide after pregnancy should be aware that:

• Sleep deprivation from newborn care can affect appetite hormones (ghrelin and leptin) and make weight management more challenging
• Postpartum hormonal shifts affect mood, energy, and metabolism in ways that are distinct from the pre-pregnancy state
• Postpartum depression and anxiety are common and can affect eating behaviors; screening and treatment are important independent of weight management goals
• Body image and identity undergo significant shifts during and after pregnancy; patience and self-compassion are important
• Caloric needs may be higher than pre-pregnancy due to physical recovery and the demands of caring for a newborn

15.4 Contraception During Resumed GLP-1 Therapy

If you are resuming semaglutide postpartum and do not wish to become pregnant again immediately, reliable contraception is once again essential. The same considerations about non-oral contraceptive methods discussed earlier apply. Many women find that the postpartum period is a natural time to establish long-acting reversible contraception, which provides both high efficacy and the convenience of not requiring daily attention during the demanding newborn period.

16. Other GLP-1 Medications and Pregnancy: Tirzepatide, Liraglutide, and More

While this guide focuses primarily on semaglutide, many women are using other GLP-1-based medications. The pregnancy considerations for each share common themes but have some differences worth noting.

16.1 Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss efficacy than semaglutide in head-to-head trials. Its pregnancy profile is similar to semaglutide in several respects:

• Animal studies showed adverse developmental effects including embryofetal death and structural abnormalities at clinically relevant exposures
• The FDA labeling recommends discontinuation before planned pregnancy
• Tirzepatide has a half-life of approximately 5 days, somewhat shorter than semaglutide’s 7 days. The recommended washout period is similarly at least 2 months before conception, based on the prescribing information
• Human pregnancy data is even more limited than for semaglutide, given tirzepatide’s more recent market entry
• The same contraception, planning, and washout principles apply

16.2 Liraglutide (Victoza, Saxenda)

Liraglutide, an older GLP-1 receptor agonist, has a shorter half-life of approximately 13 hours, meaning it clears the body much faster than semaglutide. Key distinctions include:

• The Saxenda (liraglutide 3.0 mg for weight management) prescribing information recommends stopping at least 2 months before pregnancy, consistent with the semaglutide recommendation
• Given the shorter half-life, pharmacokinetic clearance (5 half-lives) occurs within approximately 3 days, making the 2-month recommendation very conservative from a drug-elimination standpoint
• More human pregnancy exposure data exists for liraglutide than for semaglutide, given its longer time on the market
• The animal safety signals are similar to semaglutide, with embryofetal effects observed at clinically relevant doses

16.3 Dulaglutide (Trulicity)

Dulaglutide is a weekly GLP-1 receptor agonist approved for type 2 diabetes (not for weight management as a primary indication). It has a half-life of approximately 5 days and carries similar pregnancy warnings. The overall profile mirrors other GLP-1 agonists: animal data showing concern, limited human data, and a recommendation to discontinue before pregnancy.

16.4 Exenatide (Byetta, Bydureon)

Exenatide was the first GLP-1 receptor agonist on the market and has the longest real-world history. The immediate-release formulation (Byetta) has a short half-life of approximately 2.4 hours, while the extended-release formulation (Bydureon) has a longer elimination profile. Both formulations carry pregnancy warnings. The accumulated post-marketing experience with exenatide has not produced a definitive signal of increased birth defects, though formal studies are limited.

16.5 The Class-Wide Message

Across the entire GLP-1 receptor agonist class, the pregnancy guidance is consistent: no GLP-1 receptor agonist is currently considered safe for use during pregnancy. All carry animal data showing potential fetal risk, all have limited human pregnancy data, and all should be discontinued with an appropriate washout period before planned conception. The specific washout time may vary based on the half-life of the particular agent, but the 2-month minimum recommended in prescribing information provides a conservative and standardized approach.

17. Semaglutide and Male Fertility

While the majority of semaglutide-pregnancy discussions focus on women, male partners taking semaglutide also have valid questions about the medication’s impact on fertility and whether paternal exposure poses any risk to a developing pregnancy.

17.1 Animal Data on Male Reproduction

Animal fertility studies with semaglutide in male rats did not show significant adverse effects on mating behavior, fertility indices, or sperm parameters at clinically relevant doses. At very high doses (substantially above the MRHD), some studies noted reduced testes weight and altered spermatogenesis, but these findings were associated with general toxicity and reduced food intake rather than a direct reproductive effect.

17.2 Human Evidence

Human data on semaglutide’s effect on male fertility parameters is limited. Some relevant observations:

• Weight loss improves male fertility: Obesity in men is associated with reduced sperm quality, including lower sperm count, reduced motility, and increased DNA fragmentation. Weight loss from any cause, including GLP-1 therapy, tends to improve these parameters.
• Testosterone levels may improve: Obesity is associated with lower testosterone levels due to increased aromatization of testosterone to estrogen in adipose tissue. Weight loss reverses this, potentially improving both fertility and sexual function.
• No established risk of paternal exposure: There is no evidence suggesting that a man’s use of semaglutide at the time of conception poses a risk to the resulting pregnancy or fetus. The medication does not alter sperm DNA in a way that has been shown to cause birth defects.

17.3 Clinical Recommendations for Male Partners

Based on current evidence:

• There is no recommendation for men to stop semaglutide when a couple is trying to conceive
• The weight loss benefits of semaglutide may actually improve male fertility parameters
• Men with concerns about fertility should discuss all medications with their provider and consider a semen analysis if there are concerns about sperm quality
• Men planning to conceive should optimize general health factors that affect sperm quality: adequate sleep, regular exercise, limiting alcohol, avoiding tobacco, and managing stress

18. Emotional Considerations: Navigating Weight, Fertility, and Identity

The intersection of weight management, medication, and pregnancy planning touches some of the most sensitive and deeply personal aspects of a woman’s life. Clinical guidelines and pharmacokinetic tables, while essential, do not fully capture the emotional complexity of this experience. This section acknowledges that complexity and offers perspective that may be helpful.

18.1 The Fear of Weight Regain

For many women, semaglutide has been significant. After years or decades of struggling with weight, the medication may have enabled a level of weight management that felt impossible before. The prospect of stopping that medication - even temporarily, even for something as desired as pregnancy - can provoke genuine anxiety and grief.

These feelings are valid. The fear of losing progress is not vanity; it is a reasonable response to a real physiological phenomenon. Weight regain after stopping GLP-1 medications is well-documented, and for women who have experienced the health, mobility, and psychological benefits of weight loss, the thought of regression is legitimately distressing.

What may help: Recognizing that this fear is common and understandable. Talking about it openly with your healthcare provider, partner, and support network. Understanding that the medication can be resumed after pregnancy. And reframing the transition not as losing a tool, but as temporarily shifting priorities for a specific, time-limited purpose.

18.2 The Unexpected Pregnancy

Women who discover an unplanned pregnancy while on semaglutide face a uniquely stressful situation. Beyond the general emotional complexity of an unplanned pregnancy, they must contend with anxiety about medication exposure, potential judgment from healthcare providers or others, and the disruption of their weight management plan.

If this is your experience: You did not do anything reckless. Unexpected pregnancies happen, and they happen more frequently in the context of restored fertility from weight loss - a side effect that is still not universally communicated to patients starting GLP-1 medications. The available data, while limited, does not indicate a pattern of severe harm from early accidental exposure. Your feelings - whatever they are - are valid, and support is available.

18.3 The Fertility Struggle

For women who have struggled with infertility, the prospect that weight loss from semaglutide might improve their chances of conceiving can bring both hope and additional pressure. The possibility of restored ovulation is genuinely encouraging, but it is important to maintain realistic expectations and to recognize that:

• Weight loss improves fertility for weight-related causes of anovulation, but it may not address other contributing factors
• Conception may not happen immediately after achieving a target weight, and this does not mean the approach has failed
• The emotional toll of fertility struggles is significant, and integrating mental health support into the process is not a sign of weakness but of wisdom
• Multiple pathways to parenthood exist, and the outcome of the semaglutide-to-pregnancy transition does not define your worth or your process

18.4 Body Image and Pregnancy

The body changes that accompany pregnancy can be challenging for any woman, but they may carry additional emotional weight for women who have recently experienced significant weight loss. Watching the scale rise during pregnancy - even knowing it is healthy and expected - can trigger anxiety in women who have worked hard to reduce their weight.

Strategies that may help include: working with a prenatal care provider who is sensitive to your weight history, focusing on health-oriented metrics rather than scale weight alone, connecting with other mothers who have navigated similar transitions, and considering therapy or counseling if body image concerns become distressing.

18.5 The Partner Conversation

Open communication with a partner about the medication transition, the timeline, the concerns about weight, and the practical realities of the washout period can help both parties feel informed and supportive. Partners who understand why the medication must be stopped, what changes to expect, and how to be supportive during the transition can be powerful allies in the process.

18.6 Mental Health Resources

If you are experiencing significant anxiety, depression, or distress related to the semaglutide-pregnancy transition, professional mental health support is available and encouraged. Resources include:

• Your OB/GYN or primary care provider can screen for perinatal mood disorders and provide referrals
• Reproductive psychologists specialize in the emotional aspects of fertility, pregnancy loss, and family planning
• Perinatal mental health specialists focus on mental health during pregnancy and the postpartum period
• Support groups (in-person or online) for women navigating fertility, weight management, or both can provide community and shared understanding
• The Postpartum Support International helpline (1-800-944-4773) provides support for perinatal mental health concerns

19. Monitoring Schedule: Before, During, and After the Transition

A structured monitoring approach helps ensure that the transition from semaglutide to pregnancy is as safe and well-managed as possible. The following schedule provides a framework that your healthcare team may adapt to your individual needs.

This table is a general framework. Your healthcare provider will tailor the monitoring plan to your individual risk factors, medical history, and clinical needs. Women with diabetes, PCOS, a history of pregnancy complications, or other comorbidities may require more intensive monitoring. Reviewing the safety profile of GLP-1 medications can provide additional context for the monitoring considerations described here.

20. The Future of Research: Ongoing Studies and What to Watch For

The intersection of GLP-1 medications and reproductive health is one of the most rapidly evolving areas in metabolic and reproductive medicine. As millions of women of reproductive age continue to use these medications, the research space is expanding significantly.

20.1 Active and Planned Studies

Several important research initiatives are underway or in development:

• Manufacturer pregnancy registries: Both Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) maintain pregnancy exposure registries that are actively collecting data on pregnancy outcomes following drug exposure. As enrollment grows, these registries will provide increasingly meaningful data.
• Nordic registry studies: The Scandinavian countries, with their comprehensive healthcare registries and high rates of GLP-1 prescribing, are well-positioned to conduct large population-based studies linking medication exposure to pregnancy outcomes. Several such studies are in various stages of design and execution.
• Insurance claims database analyses: Large US health insurance databases are being used to identify cohorts of women who filled GLP-1 prescriptions around the time of pregnancy, with analysis of delivery outcomes, congenital malformation rates, and neonatal health.
• PCOS-specific GLP-1 studies: Multiple clinical trials are investigating the role of GLP-1 receptor agonists in PCOS management, including their effects on ovulation, fertility, and metabolic parameters. These studies will help clarify the optimal use of these medications in women seeking to conceive.
• Pre-IVF optimization studies: Research protocols are being developed to evaluate whether structured GLP-1 therapy before IVF improves assisted reproduction outcomes in women with obesity.
• Lactation transfer studies: Studies measuring semaglutide concentrations in human breast milk are needed and will eventually help inform breastfeeding guidance.

20.2 Key Questions That Remain Unanswered

As of early 2026, several critical questions remain open and will require additional research to answer:

1. What is the actual risk of birth defects from early human exposure? This is the most pressing question. Answering it requires large, well-controlled cohort studies comparing malformation rates in exposed versus unexposed pregnancies.
2. Is there a threshold dose or exposure duration below which risk is negligible? Understanding the dose-response relationship in humans would help guide risk counseling for accidental exposures.
3. Does the timing of exposure within pregnancy affect risk? Exposure during the pre-implantation period may carry a different risk profile than exposure during organogenesis.
4. What is the long-term developmental trajectory of children exposed to GLP-1 agonists in utero or periconceptionally? Long-term follow-up studies are needed to assess cognitive, growth, and metabolic outcomes.
5. Is the 2-month washout period optimal, or could a shorter period be sufficient? As more pharmacokinetic and outcome data accumulates, the washout recommendation may be refined.
6. How does semaglutide affect oocyte quality? Understanding whether the medication has direct effects on eggs (positive or negative) would inform pre-IVF and egg freezing decisions.
7. What are the effects of semaglutide in breast milk on the nursing infant? Human lactation studies are needed before evidence-based breastfeeding guidance can be developed.
8. Do the metabolic benefits of pre-pregnancy weight loss from GLP-1 therapy translate to measurably improved pregnancy outcomes compared to no treatment? Comparative effectiveness research is needed.

20.3 What This Means for Patients Now

Living in a period of evolving evidence can feel uncomfortable, but it is not unique to semaglutide. Many medications are used in practice for years before comprehensive pregnancy safety data is available. The approach outlined in this guide - following the recommended washout, using reliable contraception during treatment, optimizing preconception health, and working closely with healthcare providers - represents the most evidence-informed path available today.

As new research is published, guidelines may be updated. Your healthcare provider will be your best resource for integrating new evidence into your individual care plan. For the latest on how GLP-1 prescriptions work, including telehealth options, our prescribing guide stays current with regulatory developments.

21. Frequently Asked Questions

Below are answers to the most common questions about semaglutide and pregnancy. Each answer reflects the current state of medical evidence as of March 2026. For personalized guidance, always consult your healthcare provider.

Risk Assessment: Putting the Data in Perspective

Understanding risk in the context of pregnancy and medication exposure requires appreciating both the absolute and relative nature of the available data. This section provides a framework for thinking about the semaglutide pregnancy risk in the context of other common exposures and baseline pregnancy risks.

Baseline Pregnancy Risk Context

Every pregnancy carries a baseline level of risk for adverse outcomes, regardless of medication exposure. Understanding these baseline rates is essential for contextualizing the discussion about semaglutide:

• First-trimester miscarriage rate: Approximately 10 to 20 percent of clinically recognized pregnancies end in miscarriage, with the majority occurring in the first 12 weeks. The rate is higher when including very early losses before a pregnancy is recognized.
• Baseline rate of major birth defects: Approximately 3 percent of all live births in the United States have a major structural birth defect, regardless of medication exposure.
• Preterm birth rate: Approximately 10 percent of births in the United States are preterm (before 37 weeks of gestation).
• Low birth weight rate: Approximately 8 percent of newborns in the United States have low birth weight (under 2,500 grams).

These baseline rates mean that adverse outcomes can and do occur in pregnancies with no semaglutide exposure. When evaluating reports of problems in pregnancies where semaglutide exposure occurred, compare the rate of those problems against these baseline expectations - not against an imagined zero-risk scenario. A single case of a birth defect in a semaglutide-exposed pregnancy does not prove causation, just as a single healthy birth does not prove safety. Only large, well-controlled studies comparing outcomes in exposed and unexposed pregnancies can establish whether semaglutide actually changes these baseline risks.

The Role of Obesity Itself in Pregnancy Risk

An important nuance in the semaglutide-pregnancy discussion is that obesity itself is a well-established risk factor for pregnancy complications. Women who are taking semaglutide are often doing so because of obesity, and the pre-existing obesity carries its own risks:

• Women with BMI over 30 have approximately 2 to 3 times the risk of gestational diabetes compared to women with normal BMI
• The risk of preeclampsia is approximately 2 to 4 times higher in women with obesity
• Cesarean delivery rates are significantly higher in women with obesity, with rates increasing progressively with higher BMI categories
• Maternal obesity is associated with a 1.2 to 2.0 fold increased risk of neural tube defects, independent of folate status
• Stillbirth risk is approximately 2 times higher in women with BMI over 30 compared to normal-weight women
• Macrosomia (excessive fetal growth) is significantly more common in pregnancies complicated by maternal obesity

This context highlights the potential paradox at the heart of the semaglutide-pregnancy question: the medication must be stopped during pregnancy due to potential fetal risks, but the weight loss it produces before pregnancy may significantly reduce the obesity-related risks that would otherwise affect the pregnancy. The optimal approach - using semaglutide for pre-pregnancy weight optimization, stopping with appropriate washout, and entering pregnancy at a healthier weight - attempts to capture the benefits while avoiding the risks.

Comparing Medication Pregnancy Risk Categories

To further contextualize semaglutide’s pregnancy risk profile, it is helpful to understand where it falls relative to other commonly used medications:

This comparison illustrates that semaglutide’s pregnancy risk classification is driven primarily by the absence of reassuring human data and the presence of concerning animal data, rather than by confirmed human harm. This distinguishes it from established human teratogens like isotretinoin, where the risk is definitive and the pattern of birth defects is well-characterized. Whether semaglutide’s risk profile will be revised as more human data accumulates remains to be determined by ongoing research.

Shared Decision-Making Framework

Given the complexity and the evolving nature of the evidence, the semaglutide-pregnancy conversation is best approached through shared decision-making between the patient and her healthcare team. This means:

• Presenting the data honestly: Neither overstating the risk (which can cause unnecessary panic in women with accidental exposure) nor minimizing it (which could lead to inadequate precautions).
• Respecting patient autonomy: The decision about when to stop semaglutide, when to start trying to conceive, and how to weigh the competing priorities ultimately belongs to the patient, informed by her provider’s guidance.
• Considering the whole patient: Age, fertility window, weight-related health risks, mental health, relationship factors, career considerations, and personal values all factor into timing decisions.
• Planning for uncertainty: Developing contingency plans for unexpected outcomes (accidental pregnancy, difficulty conceiving after stopping, more weight regain than expected) reduces anxiety and improves preparedness.

Questions to Ask Your Healthcare Provider

Whether you are actively planning a pregnancy or simply want to understand your options, the following questions can guide productive conversations with your healthcare team:

1. Given my age and fertility history, what is the optimal timing for stopping semaglutide if I want to conceive within the next 1 to 2 years?
2. What contraceptive method do you recommend while I continue semaglutide treatment?
3. What preconception testing should I complete before discontinuing semaglutide?
4. If I have diabetes or insulin resistance, what medication will replace semaglutide during the washout and pregnancy?
5. What strategies do you recommend for managing weight during the washout period?
6. How will we monitor my menstrual cycles and ovulation during the washout?
7. If I become pregnant unexpectedly while on semaglutide, what is your recommended course of action?
8. What additional monitoring would you recommend during pregnancy given my history of semaglutide use?
9. When is the earliest I could safely resume semaglutide after delivery and breastfeeding?
10. Are there any newer data or guidelines about GLP-1 medications and pregnancy published recently?

Being prepared with specific questions helps ensure that your appointment time is used efficiently and that you leave with the information you need to make confident decisions.

A Note on Compounded Semaglutide

Many patients access semaglutide through compounding pharmacies rather than the branded products Ozempic and Wegovy. The pregnancy-related guidance discussed throughout this guide applies equally to compounded semaglutide. The active pharmaceutical ingredient is the same regardless of whether it comes from a brand-name product or a compounding pharmacy, and the pharmacokinetic properties (including the 7-day half-life and the recommended 2-month washout) are identical.

Compounded formulations may include different excipients (inactive ingredients) and may be delivered in different vehicles (e.g., sublingual drops, troche formulations), but the core safety considerations for pregnancy do not change based on the formulation. If you are using compounded semaglutide and planning a pregnancy, the same principles of contraception, washout, and preconception optimization apply. Our guide to GLP-1 compounding pharmacies provides additional context on these formulations.

The Bigger Picture

The semaglutide-pregnancy conversation is part of a much larger and evolving story about GLP-1 medications and women’s health. These medications have transformed the treatment of obesity and metabolic disease, and their effects on reproductive health - from fertility restoration to pregnancy planning - are increasingly recognized as clinically significant. As the medical community gathers more data and refines its understanding, the guidance provided to patients will become more specific and evidence-based.

In the meantime, the most important steps any woman can take are to be informed, to communicate openly with her healthcare providers, to use reliable contraception while on treatment, to plan ahead when pregnancy is desired, and to seek support - both medical and emotional - throughout the process. The path from GLP-1 therapy to healthy pregnancy is navigable with the right preparation, the right team, and the right information.

This guide was written to provide that information. We hope it serves you well as you make the decisions that are right for your life, your health, and your family.

Special Populations and Clinical Scenarios

Certain patient populations face unique considerations at the intersection of semaglutide and pregnancy planning. While the general principles outlined throughout this guide apply broadly, the following scenarios warrant specific attention and may benefit from multidisciplinary care involving endocrinologists, reproductive specialists, maternal-fetal medicine physicians, and mental health professionals.

Women with Type 2 Diabetes

For women using semaglutide primarily for type 2 diabetes management, the transition to pregnancy requires particularly careful planning. Diabetes in pregnancy carries significant risks including macrosomia, congenital heart defects (at approximately 2 to 5 times the baseline rate when glycemic control is poor), preeclampsia, and neonatal complications. Optimal preconception glycemic control (HbA1c ideally below 6.5 percent) reduces these risks substantially.

The medication transition plan for women with diabetes is more complex than for those using semaglutide for weight management alone. As semaglutide is discontinued, alternative glucose-lowering therapy must be initiated to prevent glycemic deterioration during the washout period and pregnancy. The primary pregnancy-safe options are insulin (the gold standard for glycemic management in pregnancy) and metformin (which has extensive safety data in pregnancy and may offer additional benefits for women with PCOS or insulin resistance). Sulfonylureas such as glyburide have also been used in gestational diabetes but have a less favorable profile than insulin or metformin for pre-existing type 2 diabetes in pregnancy. Your endocrinologist and obstetrician should collaborate on the medication transition plan, and more frequent glucose monitoring may be necessary during the weeks when semaglutide’s glycemic effects are waning but replacement therapy has not yet reached its full effect.

Women Over 35

Age-related fertility decline adds a time-sensitive dimension to the semaglutide-pregnancy conversation. Women over 35 experience a progressive decrease in both the number and quality of oocytes, and this decline accelerates after age 37 to 38. For these women, the calculus of how long to continue semaglutide for weight optimization versus when to stop and begin trying to conceive involves additional urgency.

Practical considerations for women over 35 include:

• Earlier fertility evaluation: Consider baseline fertility testing (AMH levels, antral follicle count, day 3 FSH) before or during the early phase of semaglutide treatment to understand your reproductive reserve and inform timing decisions
• Egg freezing consideration: If you want to use semaglutide for an extended period but are concerned about age-related oocyte decline, discuss whether egg freezing before or during early treatment might be appropriate
• Shorter treatment course may be advisable: Rather than waiting for maximum weight loss, it may be more appropriate to achieve a clinically meaningful amount of weight loss (even 10 to 15 percent) and then transition to pregnancy planning
• Seek evaluation sooner: If you have not conceived after 6 months of trying (rather than the 12 months recommended for women under 35), consult a reproductive endocrinologist
• Consider whether assisted reproduction is part of the plan: If IVF or other ART is anticipated, coordinate the semaglutide timeline with your fertility specialist from the outset

Women with a History of Eating Disorders

The intersection of semaglutide, weight management, and pregnancy can be particularly fraught for women with a history of eating disorders. The appetite suppression from semaglutide, the focus on weight and body changes, and the emotional complexity of pregnancy planning can interact with disordered eating patterns in complex ways.

Key considerations include ensuring that semaglutide is being used under the guidance of a provider who is aware of the eating disorder history, maintaining open communication with both the prescribing provider and any mental health professionals involved in your care, monitoring for signs that the medication or the transition process is triggering disordered eating thoughts or behaviors, and establishing a supportive framework for the body changes that pregnancy will bring. A therapist experienced in both eating disorders and perinatal mental health can be an invaluable resource during this transition.

Women Who Have Had Bariatric Surgery

Some women who have previously undergone bariatric surgery (gastric bypass, sleeve gastrectomy, or gastric banding) may also be using semaglutide for additional weight management. This population faces unique nutritional considerations during the transition to pregnancy, as bariatric surgery alters nutrient absorption and can create deficiencies in iron, calcium, vitamin B12, folate, and fat-soluble vitamins. The combination of bariatric surgery history with semaglutide’s appetite-suppressing effects may compound nutritional risks. These women typically require more intensive nutritional monitoring and supplementation during the preconception period, and should be followed by both a bariatric nutrition specialist and a prenatal care team familiar with post-surgical pregnancies.

Women Taking Multiple Medications

Many women on semaglutide take other medications for comorbid conditions - antihypertensives, lipid-lowering agents, antidepressants, thyroid medications, or medications for PCOS symptoms such as spironolactone. The preconception period requires a comprehensive medication review to identify which medications need to be stopped, which need to be switched to pregnancy-safe alternatives, and which can be safely continued. Spironolactone, for example, is a common PCOS treatment that is absolutely contraindicated in pregnancy due to its anti-androgen effects on a male fetus. ACE inhibitors and ARBs used for hypertension must be switched to pregnancy-safe alternatives such as labetalol or nifedipine. Statins should be discontinued. medication audit should ideally occur during the pre-discontinuation planning phase, well before the semaglutide washout begins, to ensure smooth transitions across all medications.

Surrogacy and Gestational Carrier Arrangements

In surrogacy arrangements, the considerations differ depending on whether the intended mother (who provides the eggs) or the gestational carrier (who carries the pregnancy) is taking semaglutide. If the intended mother is providing eggs for IVF, the question centers on whether semaglutide affects oocyte quality and whether it needs to be stopped before egg retrieval. If the gestational carrier is on semaglutide, the standard pregnancy recommendations apply: the medication must be discontinued with appropriate washout before embryo transfer. These scenarios should be coordinated by the fertility clinic managing the arrangement, with input from all relevant medical providers.

Adolescents and Young Adults

With the growing use of semaglutide in adolescents (Wegovy is approved for individuals aged 12 and older for weight management), reproductive health counseling is relevant even for younger patients who may not be actively planning pregnancy. Adolescent and young adult patients and their families should be aware that GLP-1 medications can restore fertility, that effective contraception is important during treatment, and that should the patient become sexually active, these considerations become immediately relevant. Age-appropriate reproductive health education should be part of the prescribing conversation, and providers should create a safe, non-judgmental space for these discussions.

22. Glossary of Key Terms

Anovulation

The absence of ovulation (egg release) during a menstrual cycle. Chronic anovulation is a common cause of infertility, often associated with PCOS and obesity.

AUC (Area Under the Curve)

A pharmacokinetic measure that represents the total drug exposure over time. Used to compare drug exposures between species and between doses in safety studies.

Cmax

The maximum (peak) concentration of a drug in the blood after a dose. Relevant to the discussion of oral contraceptive absorption during GLP-1 therapy.

DPP-4 (Dipeptidyl Peptidase-4)

An enzyme that rapidly breaks down natural GLP-1 in the body. Semaglutide is engineered to resist DPP-4 degradation, giving it its long half-life.

Embryofetal Mortality

Death of the embryo or fetus during development. Observed in animal studies of semaglutide at high doses.

FAERS (FDA Adverse Event Reporting System)

The FDA database that collects reports of adverse events, medication errors, and product quality complaints for marketed drugs.

Gastric Emptying

The process by which food leaves the stomach and enters the small intestine. Semaglutide significantly slows gastric emptying, which contributes to appetite suppression but may affect oral medication absorption.

Gestational Diabetes Mellitus (GDM)

Diabetes that develops during pregnancy in women who did not have diabetes before becoming pregnant. Obesity is a major risk factor.

GLP-1 (Glucagon-Like Peptide-1)

A natural hormone produced by L-cells in the small intestine that regulates blood sugar, appetite, and gastric emptying. Semaglutide is a synthetic analog that mimics and extends GLP-1 activity.

GLP-1 Receptor Agonist

A class of medications that activate GLP-1 receptors to produce effects similar to natural GLP-1 but with much longer duration. Includes semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide.

Half-Life (Elimination)

The time it takes for the concentration of a drug in the blood to decrease by 50 percent. Semaglutide has a half-life of approximately 7 days.

Hyperinsulinemia

Abnormally elevated insulin levels in the blood, typically resulting from insulin resistance. Contributes to ovulatory dysfunction in PCOS by stimulating excess ovarian androgen production.

HPO Axis (Hypothalamic-Pituitary-Ovarian Axis)

The hormonal feedback system that controls reproductive function. Disruption of the HPO axis by obesity, stress, or metabolic factors can cause anovulation and infertility.

LARC (Long-Acting Reversible Contraception)

Contraceptive methods that provide highly effective, long-term pregnancy prevention with a single action. Includes IUDs and subdermal implants. Recommended for women on GLP-1 therapy due to high efficacy and no GI absorption concerns.

Macrosomia

A condition in which a newborn is significantly larger than average, typically defined as birth weight over 4,000 grams (about 8 pounds, 13 ounces). Associated with maternal obesity and gestational diabetes.

MRHD (Maximum Recommended Human Dose)

The highest dose of a drug that is approved for use in humans. Animal study findings are often reported in terms of multiples of the MRHD to provide clinical context.

Organogenesis

The period during embryonic development when major organs form, approximately weeks 3 through 8 after conception. This is the window of highest vulnerability for structural birth defects from drug exposure.

PCOS (Polycystic Ovary Syndrome)

A common hormonal disorder affecting 8 to 13 percent of women of reproductive age. Characterized by irregular periods, excess androgen levels, and polycystic ovarian morphology on ultrasound. Strongly associated with insulin resistance and obesity.

Pharmacovigilance

The science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems after a medication reaches the market.

Preeclampsia

A serious pregnancy complication characterized by high blood pressure and often protein in the urine, typically developing after 20 weeks of gestation. Maternal obesity is a significant risk factor.

PLLR (Pregnancy and Lactation Labeling Rule)

The FDA regulation (effective 2015) that replaced the older pregnancy letter-category system (A, B, C, D, X) with narrative summaries of available data in prescription drug labeling.

SHBG (Sex Hormone-Binding Globulin)

A protein that binds to sex hormones (including testosterone and estrogen) in the blood. Low SHBG levels in obesity lead to higher free androgen levels, contributing to PCOS symptoms.

Tmax

The time at which the maximum concentration (Cmax) of a drug is reached in the blood after dosing. Semaglutide-induced delayed gastric emptying can increase Tmax for orally administered drugs.

Washout Period

The time required after stopping a medication for the drug to be substantially eliminated from the body. For semaglutide, the recommended washout before conception is at least 2 months.

23. References and Further Reading

The following references provide the scientific foundation for the information presented in this guide. They include FDA labeling documents, published clinical studies, regulatory guidance, and clinical practice guidelines.

1. Ozempic (semaglutide) Prescribing Information. Novo Nordisk A/S. Revised 2025. Section 8.1 Pregnancy, Section 8.2 Lactation.
2. Wegovy (semaglutide) Prescribing Information. Novo Nordisk A/S. Revised 2025. Section 8.1 Pregnancy, Section 8.2 Lactation.
3. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. Revised 2025. Section 8.1 Pregnancy.
4. European Medicines Agency. Ozempic Summary of Product Characteristics. Section 4.6 Fertility, pregnancy and lactation.
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
6. Rubino DM, Greenway FL, Khalid U, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
7. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564.
8. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.
9. Obesity in Pregnancy. ACOG Practice Bulletin No. 230. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2021;137(6):e128-e144.
10. Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington (DC): National Academies Press; 2009.
11. Jain T, Negris O, Engmann L. GLP-1 Receptor Agonists and Fertility: Separating Signal from Noise. Fertil Steril. 2025.
12. American Society of Anesthesiologists. ASA Guidance on GLP-1 Receptor Agonists and Perioperative Considerations. Updated 2025.
13. LactMed Drugs and Lactation Database. National Library of Medicine. Semaglutide entry. Updated 2025.
14. Pregnancy and Lactation Labeling Rule (PLLR). FDA Final Rule. Federal Register. 2014;79(233):72064-72103.
15. Rasmussen KM, Yaktine AL, eds. Weight Gain During Pregnancy: Reexamining the Guidelines. Institute of Medicine. 2009.

Related FormBlends Guides

• What Is GLP-1? How This Hormone Controls Weight and Blood Sugar
• GLP-1 Weight Loss Medications: Complete Guide to Semaglutide, Tirzepatide, and More
• Is GLP-1 Safe? Side Effects, Long-Term Risks, and Safety Profile
• GLP-1 and Insulin Resistance: How These Medications Improve Metabolic Health
• How to Get a GLP-1 Prescription Online: Telehealth Options and Requirements
• GLP-1 Compounding Pharmacy: What You Need to Know

⚠️ Medical Disclaimer Reminder

The information in this article is provided for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Decisions about medication use during pregnancy planning, pregnancy, and breastfeeding should always be made in consultation with qualified healthcare providers who understand your individual medical history and circumstances.

FormBlends does not practice medicine and does not recommend for or against any pregnancy decisions. If you are pregnant, may be pregnant, or are planning a pregnancy while using any GLP-1 medication, please contact your healthcare provider immediately.

Last reviewed: March 2026  |  Medical review by: Dr. Michael Torres, MD; Dr. Sarah Chen, PharmD